<DOC>
	<DOCNO>NCT01502696</DOCNO>
	<brief_summary>Patients ulcerated melanoma Breslow &gt; 1 mm , N0M0 significantly high risk relapse patient non-ulcerated primary 40-50 % chance develop stage IV disease almost invariably succumb . In stage I II patient ulcerated primary sentinel node ( SN-staged ) find SN-negative still 25-30 % relapse risk . The purpose study evaluate effectiveness safety treat PEG IFN alfa-2b 2 year compare observation ( treatment ) , administer adequate surgery perform ulcerated primary cutaneous melanoma .</brief_summary>
	<brief_title>Adjuvant PEG Intron Ulcerated Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Subjects must 1870 year old . Subjects must histologically document ulcerated primary cutaneous melanoma T ( 24 ) b N0M0 . Adequate resection ulcerate primary cutaneous melanoma . 1 2 cm normal tissue excision margin accord Breslow thickness recommend . In head neck area case location distally extremity , narrow margin acceptable long radical ( see Appendix F ) . Subjects must recover effect recent surgery . SNB must occur within 12 week prior randomization . Subjects must ECOG performance status 0 1 ( See Appendix B ) . Subjects must adequate bone marrow , renal hepatic function define follow parameter obtain maximum 12 week prior randomization : Hematology : WBC &gt; = 3.0 x 109/L Neutrophils &gt; 1.5 x 109/L Platelets &gt; 100 x 109/L Hemoglobin &gt; = 9 g/dL 5.6 mmol/L Adequate Renal Hepatic function : Serum creatinine &lt; 2.0 mg/dL &lt; 140 Âµmol/L SGOT SGPT &lt; 2 time upper normal limit laboratory normal ( ULN ) No mucosal melanoma ocular melanoma . No evidence nodal involvement confirm sentinel lymph node biopsy ( SNB ) . Sentinel Node stag excision primary must do date final excision primary date randomization . No evidence regional distant lymph node metastases satellites/intransit metastasis ( even resect ) . No evidence distant metastasis clinical examination , CT/MRI full chest , abdomen pelvis . Neck CT/MRI head neck primary . No clinical evidence brain metastasis . No pregnant woman No breast feed woman No patient medical condition require chronic systemic corticosteroid eligible . No experimental therapy within 30 day prior randomization study . No prior chemotherapy , immunotherapy/vaccine , hormonal radiation therapy melanoma . No prior treatment interferonalfa reason . No history prior malignancy within past 5 year surgically cure nonmelanoma skin cancer cervical carcinoma situ . No severe cardiovascular disease , i.e . arrhythmias require chronic treatment , congestive heart failure ( NYHA Class III IV ) symptomatic ischemic heart disease . No thyroid dysfunction responsive therapy . No poorly control ( HBA1C &gt; 8 % ) diabetes mellitus uncontrolled diabetes mellitus , i.e . elevate fast serum glucose &lt; 110 % ULN ) . No active autoimmune disease . No active and/or uncontrolled infection , include active hepatitis . No history seropositivity HIV . No history neuropsychiatric disorder require hospitalization . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ulcerated primary cutaneous melanoma</keyword>
	<keyword>Stage II</keyword>
	<keyword>PEG IFN alfa-2b</keyword>
	<keyword>T ( 2-4 ) bN0M0</keyword>
</DOC>